Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

作者：Francesco Passamonti, Francesca Palandri, Güray Saydam, Jeannie Callum, Timothy Devos, Paola Guglielmelli, Alessandro M. Vannucchi, Evren Zor, Mike W. Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Grießhammer · 发表于：The Lancet Haematology · 年份：2022 · DOI：10.1016/s2352-3026(22)00102-8 · 被引用次数：47 · 研究领域：Myeloproliferative Neoplasms: Diagnosis and Treatment、Systemic Sclerosis and Related Diseases、Intracerebral and Subarachnoid Hemorrhage Research